Factors inducing cutaneous adverse reactions in cancer patients treated with PD-1 and PD-L1 inhibitors: a machine-learning algorithm approach.

Journal: Immunopharmacology and immunotoxicology
PMID: 39542723

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) show promise in cancer treatment but can lead to immune-related adverse events (irAEs), notably affecting the skin. Understanding the factors behind these skin reactions is crucial for effective management during treatment. Hence, the aim of this study was to uncover associations between patient characteristics and cutaneous adverse reactions among cancer patients undergoing ICI treatment.

Authors

  • Young-Ah Cho
    The Prime Hospital, Jinju, Gyeongsangnam-do, Republic of Korea.
  • Youngyun Moon
    College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea.
  • Wooyoung Park
    Department of Biomedical Engineering, City University of Hong Kong, Kowloong Tong, Hong Kong, China.
  • Yerin Lee
    Department of Biomedical Engineering, College of Health Science, Yonsei University, Wonju, Kangwon-do, Republic of Korea.
  • Kyung-Eun Lee
    Department of Oral Medicine, School of Dentistry, Jeonbuk National University, Jeonju, Korea.
  • Dong-Chul Kim
    Department of Pathology, Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Republic of Korea.
  • Woorim Kim
    College of Pharmacy, Chungbuk National University, 660-1 Yeonje-ri, Osong-eup, Heungdeok-gu, Cheongju, 28160, Republic of Korea.

Keywords

External Resources

Popular Topics
Recent Journals